Shopping Cart 0
Cart Subtotal
AED 0

Massachusetts Institute of Technology - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Massachusetts Institute of Technology (MIT) is a research university that offers contract research and education services. The university offers education in the areas of computer science, biology, aeronautics, mechanical engineering, civil engineering, economics, electrical engineering, literature, architecture, chemistry, mathematics, political science, history, linguistics, nuclear science, physics, and music and theater arts. It conducts research in the fields of neuroscience, humanities, anthropology, cancer, astronomy, oceanography, nuclear science, cognitive science, nanoscience, and nanotechnology. The university offers extracurricular activities like sports, music, dance, arts and athletics, among others. MIT is headquartered in Cambridge, Massachusetts, the US.

Massachusetts Institute of Technology-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Massachusetts Institute of Technology, Medical Devices Deals, 2012 to YTD 2018 10

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deal Details 14

Partnerships 14

CureMeta Enters into Research Agreement with Whitehead Institute for Biomedical Research 14

AstraZeneca Enters into Research Agreement with Broad Institute and Whitehead Institute 15

White Head Institute And Biogen Idec Enter Into Reasearch Agreement 16

Licensing Agreements 17

Trovagene Enters into Patent Licensing Agreement with Massachusetts Institute of Technology 17

Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard, MIT, Wageningen University, and University of Tokyo 18

Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, Massachusetts Institute of Technology and University of Iowa 20

Cognito Therapeutics Enters into Licensing Agreement with Massachusetts Institute of Technology 22

Rubius Therapeutics Enters into Licensing Agreement with Whitehead Institute for Biomedical Research 23

Gensight Biologics Exercises its Option Agreement with Massachusetts Institute of Technology 24

Frequency Therapeutics Receives Intellectual Property Rights from MIT and Harvard Medical School 25

Juniper Pharma Enters into Licensing Agreement with Harvard Medical, Massachusetts General Hospital and Massachusetts Institute of Technology 26

Columbia Labs Enters into Licensing Agreement for IVR Technology 28

Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, and Massachusetts Institute of Technology 29

SQZ Biotec Enters into License Agreement with Massachusetts Institute of Technology 31

Visterra Enters into Licensing Agreement with MIT for Dengue Virus Antibodies 32

Shire Amends Licensing Agreement with Massachusetts Institute of Technology 33

Syros Pharma Enters into Licensing Agreement with Whitehead Institute 34

Syros Pharma Enters into Licensing Agreement with Dana-Farber and Whitehead 35

MetaStat Enters Into Licensing Agreements For Alternative Splicing Program 37

Massachusetts Institute of Technology-Key Competitors 39

Massachusetts Institute of Technology-Key Employees 40

Massachusetts Institute of Technology-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Recent Developments 42

Corporate Communications 42

May 16, 2018: Ashley Smart named associate director of the Knight Science Journalism Program 42

Apr 30, 2018: Elazer Edelman named director of Institute for Medical Engineering and Science 43

Legal and Regulatory 44

Sep 10, 2018: CRISPR Therapeutics, Intellia Therapeutics & Caribou Biosciences provide update on US federal circuit decision upholding the ruling by US patent and trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology 44

Government and Public Interest 45

Oct 04, 2018: To improve anesthesia, focus on neuroscience and nociception, experts urge 45

Aug 24, 2018: CPRIT Surpasses USD 2 Billion Milestone with 64 New Grants 47

Aug 22, 2018: Study: Cellular changes lead to chronic allergic inflammation in the sinus 53

Aug 20, 2018: Biological engineers discover new antibiotic candidates 55

Aug 06, 2018: A targeted approach to treating glioma 57

Jul 16, 2018: New materials improve delivery of therapeutic messenger RNA 58

Jul 06, 2018: MIT: Automating molecule design to speed up drug development 60

Jun 21, 2018: Lustgarten Funded Study Shows Loss of Fat and Muscle is a Common First Sign of Pancreatic Cancer 62

Jun 08, 2018: USD 8.1 million grant funds new center to research highly aggressive form of lung cancer 63

May 31, 2018: Neuroscientists discover roles of gene linked to Alzheimer's 65

Apr 16, 2018: Artificial antimicrobial peptides could help overcome drug-resistant bacteria 67

Apr 06, 2018: Fluorescent dye could enable sharper biological imaging 69

Mar 22, 2018: Study suggests method for boosting growth of blood vessels and muscle 71

Mar 06, 2018: New study solves an arthritis drug mystery 73

Jan 31, 2018: Towards an early diagnosis of Parkinson's disease from the speech 75

Jan 09, 2018: New drug capsule may allow weekly HIV treatment 76

Oct 12, 2017: New technique scours the genome for genes that combat disease 78

Sep 20, 2017: Space research institute awards 10 research grants 80

Sep 14, 2017: Massachusetts Institute of Technology: One vaccine injection could carry many doses 82

Sep 04, 2017: Study suggests simple way to predict preterm births 84

Jul 20, 2017: Study Predicts Heart Cells' Response to Dwindling Oxygen 86

Jul 19, 2017: DARPA: Building the Safe Genes Toolkit 88

Jul 12, 2017: Antibiotic Nanoparticles Fight Drug-resistant Bacteria 91

Mar 20, 2017: Tethered nanoparticles make tumor cells more vulnerable 93

Feb 10, 2017: U.S. Scientists Receive Inaugural USD 87 Million Grand Challenge Awards To Accelerate Global Progress To Beat Cancer Sooner 95

Product News 96

Jun 18, 2018: Tiny particles could help in fight against brain cancer 96

05/21/2018: A single-injection vaccine for the polio virus 97

Apr 18, 2017: Long-lasting drug delivery system may help decrease the spread of malaria 99

Mar 14, 2018: MIT developed Body on a chip could improve drug evaluation 100

Feb 27, 2017: New technology offers fast peptide synthesis 102

Jan 09, 2018: Slow-Release Pill Developed to Deliver HIV Therapeutics 104

Other Significant Developments 105

Aug 10, 2018: Study suggests glaucoma may be an autoimmune disease 105

Aug 09, 2018: Artificial intelligence model learns from patient data to make cancer treatment less toxic 107

Jun 27, 2018: Personalized deep learning equips robots for autism therapy 109

May 31, 2018: A thymic cell study programme for developing an ambitious transplant strategy 111

Appendix 112

Methodology 112

About GlobalData 112

Contact Us 112

Disclaimer 112


List Of Figure

List of Figures

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Massachusetts Institute of Technology, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Key Facts 2

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Massachusetts Institute of Technology, Deals By Therapy Area, 2012 to YTD 2018 9

Massachusetts Institute of Technology, Medical Devices Deals, 2012 to YTD 2018 10

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

CureMeta Enters into Research Agreement with Whitehead Institute for Biomedical Research 14

AstraZeneca Enters into Research Agreement with Broad Institute and Whitehead Institute 15

White Head Institute And Biogen Idec Enter Into Reasearch Agreement 16

Trovagene Enters into Patent Licensing Agreement with Massachusetts Institute of Technology 17

Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard, MIT, Wageningen University, and University of Tokyo 18

Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, Massachusetts Institute of Technology and University of Iowa 20

Cognito Therapeutics Enters into Licensing Agreement with Massachusetts Institute of Technology 22

Rubius Therapeutics Enters into Licensing Agreement with Whitehead Institute for Biomedical Research 23

Gensight Biologics Exercises its Option Agreement with Massachusetts Institute of Technology 24

Frequency Therapeutics Receives Intellectual Property Rights from MIT and Harvard Medical School 25

Juniper Pharma Enters into Licensing Agreement with Harvard Medical, Massachusetts General Hospital and Massachusetts Institute of Technology 26

Columbia Labs Enters into Licensing Agreement for IVR Technology 28

Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, and Massachusetts Institute of Technology 29

SQZ Biotec Enters into License Agreement with Massachusetts Institute of Technology 31

Visterra Enters into Licensing Agreement with MIT for Dengue Virus Antibodies 32

Shire Amends Licensing Agreement with Massachusetts Institute of Technology 33

Syros Pharma Enters into Licensing Agreement with Whitehead Institute 34

Syros Pharma Enters into Licensing Agreement with Dana-Farber and Whitehead 35

MetaStat Enters Into Licensing Agreements For Alternative Splicing Program 37

Massachusetts Institute of Technology, Key Competitors 39

Massachusetts Institute of Technology, Key Employees 40

Massachusetts Institute of Technology, Subsidiaries 41

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Massachusetts Institute of Technology, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Massachusetts Institute of Technology (MIT) is a research university that offers contract research and education services. The university offers education in the areas of computer science, biology, aeronautics, mechanical engineering, civil engineering, economics, electrical engineering, literature, architecture, chemistry, mathematics, political science, history, linguistics, nuclear science, physics, and music and theater arts. It conducts research in the fields of neuroscience, humanities, anthropology, cancer, astronomy, oceanography, nuclear science, cognitive science, nanoscience, and nanotechnology. The university offers extracurricular activities like sports, music, dance, arts and athletics, among others. MIT is headquartered in Cambridge, Massachusetts, the US.

Massachusetts Institute of Technology-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Massachusetts Institute of Technology, Medical Devices Deals, 2012 to YTD 2018 10

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deal Details 14

Partnerships 14

CureMeta Enters into Research Agreement with Whitehead Institute for Biomedical Research 14

AstraZeneca Enters into Research Agreement with Broad Institute and Whitehead Institute 15

White Head Institute And Biogen Idec Enter Into Reasearch Agreement 16

Licensing Agreements 17

Trovagene Enters into Patent Licensing Agreement with Massachusetts Institute of Technology 17

Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard, MIT, Wageningen University, and University of Tokyo 18

Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, Massachusetts Institute of Technology and University of Iowa 20

Cognito Therapeutics Enters into Licensing Agreement with Massachusetts Institute of Technology 22

Rubius Therapeutics Enters into Licensing Agreement with Whitehead Institute for Biomedical Research 23

Gensight Biologics Exercises its Option Agreement with Massachusetts Institute of Technology 24

Frequency Therapeutics Receives Intellectual Property Rights from MIT and Harvard Medical School 25

Juniper Pharma Enters into Licensing Agreement with Harvard Medical, Massachusetts General Hospital and Massachusetts Institute of Technology 26

Columbia Labs Enters into Licensing Agreement for IVR Technology 28

Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, and Massachusetts Institute of Technology 29

SQZ Biotec Enters into License Agreement with Massachusetts Institute of Technology 31

Visterra Enters into Licensing Agreement with MIT for Dengue Virus Antibodies 32

Shire Amends Licensing Agreement with Massachusetts Institute of Technology 33

Syros Pharma Enters into Licensing Agreement with Whitehead Institute 34

Syros Pharma Enters into Licensing Agreement with Dana-Farber and Whitehead 35

MetaStat Enters Into Licensing Agreements For Alternative Splicing Program 37

Massachusetts Institute of Technology-Key Competitors 39

Massachusetts Institute of Technology-Key Employees 40

Massachusetts Institute of Technology-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Recent Developments 42

Corporate Communications 42

May 16, 2018: Ashley Smart named associate director of the Knight Science Journalism Program 42

Apr 30, 2018: Elazer Edelman named director of Institute for Medical Engineering and Science 43

Legal and Regulatory 44

Sep 10, 2018: CRISPR Therapeutics, Intellia Therapeutics & Caribou Biosciences provide update on US federal circuit decision upholding the ruling by US patent and trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology 44

Government and Public Interest 45

Oct 04, 2018: To improve anesthesia, focus on neuroscience and nociception, experts urge 45

Aug 24, 2018: CPRIT Surpasses USD 2 Billion Milestone with 64 New Grants 47

Aug 22, 2018: Study: Cellular changes lead to chronic allergic inflammation in the sinus 53

Aug 20, 2018: Biological engineers discover new antibiotic candidates 55

Aug 06, 2018: A targeted approach to treating glioma 57

Jul 16, 2018: New materials improve delivery of therapeutic messenger RNA 58

Jul 06, 2018: MIT: Automating molecule design to speed up drug development 60

Jun 21, 2018: Lustgarten Funded Study Shows Loss of Fat and Muscle is a Common First Sign of Pancreatic Cancer 62

Jun 08, 2018: USD 8.1 million grant funds new center to research highly aggressive form of lung cancer 63

May 31, 2018: Neuroscientists discover roles of gene linked to Alzheimer's 65

Apr 16, 2018: Artificial antimicrobial peptides could help overcome drug-resistant bacteria 67

Apr 06, 2018: Fluorescent dye could enable sharper biological imaging 69

Mar 22, 2018: Study suggests method for boosting growth of blood vessels and muscle 71

Mar 06, 2018: New study solves an arthritis drug mystery 73

Jan 31, 2018: Towards an early diagnosis of Parkinson's disease from the speech 75

Jan 09, 2018: New drug capsule may allow weekly HIV treatment 76

Oct 12, 2017: New technique scours the genome for genes that combat disease 78

Sep 20, 2017: Space research institute awards 10 research grants 80

Sep 14, 2017: Massachusetts Institute of Technology: One vaccine injection could carry many doses 82

Sep 04, 2017: Study suggests simple way to predict preterm births 84

Jul 20, 2017: Study Predicts Heart Cells' Response to Dwindling Oxygen 86

Jul 19, 2017: DARPA: Building the Safe Genes Toolkit 88

Jul 12, 2017: Antibiotic Nanoparticles Fight Drug-resistant Bacteria 91

Mar 20, 2017: Tethered nanoparticles make tumor cells more vulnerable 93

Feb 10, 2017: U.S. Scientists Receive Inaugural USD 87 Million Grand Challenge Awards To Accelerate Global Progress To Beat Cancer Sooner 95

Product News 96

Jun 18, 2018: Tiny particles could help in fight against brain cancer 96

05/21/2018: A single-injection vaccine for the polio virus 97

Apr 18, 2017: Long-lasting drug delivery system may help decrease the spread of malaria 99

Mar 14, 2018: MIT developed Body on a chip could improve drug evaluation 100

Feb 27, 2017: New technology offers fast peptide synthesis 102

Jan 09, 2018: Slow-Release Pill Developed to Deliver HIV Therapeutics 104

Other Significant Developments 105

Aug 10, 2018: Study suggests glaucoma may be an autoimmune disease 105

Aug 09, 2018: Artificial intelligence model learns from patient data to make cancer treatment less toxic 107

Jun 27, 2018: Personalized deep learning equips robots for autism therapy 109

May 31, 2018: A thymic cell study programme for developing an ambitious transplant strategy 111

Appendix 112

Methodology 112

About GlobalData 112

Contact Us 112

Disclaimer 112


List Of Figure

List of Figures

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Massachusetts Institute of Technology, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Key Facts 2

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Massachusetts Institute of Technology, Deals By Therapy Area, 2012 to YTD 2018 9

Massachusetts Institute of Technology, Medical Devices Deals, 2012 to YTD 2018 10

Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

CureMeta Enters into Research Agreement with Whitehead Institute for Biomedical Research 14

AstraZeneca Enters into Research Agreement with Broad Institute and Whitehead Institute 15

White Head Institute And Biogen Idec Enter Into Reasearch Agreement 16

Trovagene Enters into Patent Licensing Agreement with Massachusetts Institute of Technology 17

Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard, MIT, Wageningen University, and University of Tokyo 18

Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, Massachusetts Institute of Technology and University of Iowa 20

Cognito Therapeutics Enters into Licensing Agreement with Massachusetts Institute of Technology 22

Rubius Therapeutics Enters into Licensing Agreement with Whitehead Institute for Biomedical Research 23

Gensight Biologics Exercises its Option Agreement with Massachusetts Institute of Technology 24

Frequency Therapeutics Receives Intellectual Property Rights from MIT and Harvard Medical School 25

Juniper Pharma Enters into Licensing Agreement with Harvard Medical, Massachusetts General Hospital and Massachusetts Institute of Technology 26

Columbia Labs Enters into Licensing Agreement for IVR Technology 28

Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, and Massachusetts Institute of Technology 29

SQZ Biotec Enters into License Agreement with Massachusetts Institute of Technology 31

Visterra Enters into Licensing Agreement with MIT for Dengue Virus Antibodies 32

Shire Amends Licensing Agreement with Massachusetts Institute of Technology 33

Syros Pharma Enters into Licensing Agreement with Whitehead Institute 34

Syros Pharma Enters into Licensing Agreement with Dana-Farber and Whitehead 35

MetaStat Enters Into Licensing Agreements For Alternative Splicing Program 37

Massachusetts Institute of Technology, Key Competitors 39

Massachusetts Institute of Technology, Key Employees 40

Massachusetts Institute of Technology, Subsidiaries 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Massachusetts Institute of Technology, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.